Explore

University of Pennsylvania Researchers Identify Underreported Side Effects of Weight-Loss Drugs Using AI

University of Pennsylvania Researchers Identify Underreported Side Effects of Weight-Loss Drugs Using AI

Researchers at the University of Pennsylvania have utilized artificial intelligence to analyze over 400,000 Reddit posts, uncovering potential side effects of GLP-1 drugs, such as semaglutide and tirzepatide, which are commonly used for weight loss and diabetes management. The study, published in Nature Health, highlights symptoms that may not be fully documented in clinical trials, including reproductive issues like irregular menstrual cycles and temperature-related effects such as chills and hot flashes. The research points to the value of social media in providing early insights into drug safety, as patients share experiences that may not be captured in traditional clinical settings.

Eli Lilly Confirms Safety of Foundayo in ACHIEVE-4 Trial, Aiming for Diabetes Approval

Eli Lilly Confirms Safety of Foundayo in ACHIEVE-4 Trial, Aiming for Diabetes Approval

Eli Lilly Confirms Safety of Foundayo in ACHIEVE-4 Trial, Aiming for Diabetes Approval

GLP-1 Medications Show Varied Effectiveness in Weight Loss, Prompting Alternative Approaches

GLP-1 Medications Show Varied Effectiveness in Weight Loss, Prompting Alternative Approaches

Recent research highlights that GLP-1 medications, such as Wegovy, are not universally effective for weight loss, with up to 20% of users not responding to the treatment. A study published in the journal Obesity Science and Practice suggests that combining GLP-1 drugs with other medications, like Contrave, which combines naltrexone and bupropion, may enhance effectiveness for those who do not respond to GLP-1s alone. The study emphasizes the need for a multi-pronged approach to obesity treatment, as individual responses to these medications can vary significantly. This combination therapy targets the gut-brain axis, potentially reducing food cravings and improving weight loss outcomes.

Eli Lilly's Foundayo Demonstrates Safety and Efficacy in ACHIEVE-4 Trial for Type 2 Diabetes

Eli Lilly's Foundayo Demonstrates Safety and Efficacy in ACHIEVE-4 Trial for Type 2 Diabetes

Eli Lilly's Foundayo Demonstrates Safety and Efficacy in ACHIEVE-4 Trial for Type 2 Diabetes

Novo Nordisk Gains Edge Over Eli Lilly in Weight-Loss Drug Competition

Novo Nordisk Gains Edge Over Eli Lilly in Weight-Loss Drug Competition

Novo Nordisk Gains Edge Over Eli Lilly in Weight-Loss Drug Competition

Researchers Propose New Obesity Drug Approach, Dropping GLP-1 Target

Researchers Propose New Obesity Drug Approach, Dropping GLP-1 Target

Researchers Propose New Obesity Drug Approach, Dropping GLP-1 Target

Eli Lilly's Foundayo Shows Promising Results in Phase 3 Diabetes Study

Eli Lilly's Foundayo Shows Promising Results in Phase 3 Diabetes Study

Eli Lilly's Foundayo Shows Promising Results in Phase 3 Diabetes Study

Kailera soars over 60% in Nasdaq debut as weight-loss drug race heats up

Kailera soars over 60% in Nasdaq debut as weight-loss drug race heats up

By Manya Saini April 17 (Reuters) - Weight-loss drug developer Kailera Therapeutics' shares surged 62.5% in their Nasdaq debut on Friday after closing a $625 million U.S. initial public offering, as Wall Street's appetite for the fast-growing market remains unsated.

Cochrane Review Finds Anti-Amyloid Alzheimer's Drugs Ineffective and Risky

Cochrane Review Finds Anti-Amyloid Alzheimer's Drugs Ineffective and Risky

A recent review by the Cochrane Collaboration has concluded that anti-amyloid drugs, which target amyloid beta proteins in the brain, do not provide clinically meaningful benefits for patients with Alzheimer's disease. The review analyzed data from 17 clinical trials involving 20,342 participants with mild cognitive impairment or mild dementia due to Alzheimer's. Despite the removal of amyloid proteins from the brain, these drugs did not significantly impact cognitive decline or dementia severity. Furthermore, the review highlighted an increased risk of brain swelling and bleeding associated with these drugs, although most patients did not exhibit symptoms. The findings suggest that while these drugs can remove amyloid proteins, this does not translate into a meaningful clinical benefit for patients.

Cochrane Review Finds Limited Benefit in Alzheimer's Amyloid Drugs

Cochrane Review Finds Limited Benefit in Alzheimer's Amyloid Drugs

A Cochrane Collaboration review has concluded that amyloid beta-targeting drugs for Alzheimer's disease offer minimal clinical benefit. The analysis of 17 clinical trials involving 20,342 participants found that these drugs have negligible effects on cognitive decline and dementia severity, while increasing the risk of brain bleeding and swelling. The review included trials of approved therapies like Eisai/Biogen's Leqembi and Eli Lilly's Kisunla. Despite statistical significance in early trials, the review emphasizes the lack of meaningful clinical impact, prompting calls for research into alternative treatment mechanisms.

GLP-1 Medications Gain Popularity for Cosmetic Weight Loss Among Non-Celebrities

GLP-1 Medications Gain Popularity for Cosmetic Weight Loss Among Non-Celebrities

GLP-1 Medications Gain Popularity for Cosmetic Weight Loss Among Non-Celebrities

Study Links Common IBS Medications to Increased Risk of Death

Study Links Common IBS Medications to Increased Risk of Death

A study by Cedars-Sinai Health Sciences University has found that certain medications used to treat irritable bowel syndrome (IBS) may be associated with an increased risk of death. The study analyzed health records of over 650,000 adults and found that long-term use of antidepressants was linked to a 35% increase in death risk, while opioid-based antidiarrheal medications doubled the risk. The study does not prove causation but suggests a need for caution in long-term use of these medications.